Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2023.12.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Nicholas J Short und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: nshort@mdanderson.org. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Cardiovascular Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, "dose-dense" administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes. PATIENTS AND METHODS: We performed a retrospective analysis of the safety and efficacy of a dose-dense regimen of mini-hyper-CVD (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with mini-methotrexate and cytarabine), INO, and blinatumomab in patients with B-cell ALL. RESULTS: Twenty-one patients were treated (frontline, n = 9; MRD consolidation, n = 4; relapsed/refractory, n = 8). In the frontline cohort, all patients achieved CR/CRi and MRD negativity by flow cytometry at the end of cycle 1. Across the frontline and MRD consolidation cohorts, 10/11 patients (91%) achieved next-generation sequencing MRD negativity at a sensitivity of 10-6, including 6/10 evaluable patients (60%) who achieved next-generation sequencing MRD negativity after cycle 1. The CR/CRi rate in the relapsed/refractory cohort was 63%, and all responders achieved MRD negativity by flow cytometry at the end of cycle 1. The 1-year overall survival rate for the combined cohort of the frontline and MRD-positive patients was 83%. No new safety signals were observed with the dose-dense mini-hyper-CVD, INO, and blinatumomab regimen. CONCLUSION: Dose-dense delivery of mini-hyper-CVD, INO, and blinatumomab was safe and resulted in rapid and deep MRD negativity in patients with B-cell ALL. This regimen is now being prospectively evaluated in both the frontline and relapsed/refractory settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: nshort@mdanderson.org.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Short, N. J., Jabbour, E., Jamison, T., Paul, S., Cuglievan, B., McCall, D., Gibson, A., Jain, N., Haddad, F. G., Nasr, L. F., Marx, K. R., Rausch, C., Savoy, J. M., Garris, R., Ravandi, F., & Kantarjian, H. (2024). Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.12.016
Vancouver
Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, et al. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.12.016
BibTeX
@article{Short2024,
author = {Short, Nicholas J and Jabbour, Elias and Jamison, Trevor and Paul, Shilpa and Cuglievan, Branko and McCall, David and Gibson, Amber and Jain, Nitin and Haddad, Fadi G and Nasr, Lewis F and Marx, Kayleigh R and Rausch, Caitlin and Savoy, J Michael and Garris, Rebecca and Ravandi, Farhad and Kantarjian, Hagop},
title = {Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2023.12.016}
}
EUVIMED